
Will the FDA approve any psychedelic substance for medical use this year?
K 452.7K contracts
1
1

- Reported volume
- K 452.7K contracts
- Events
- 1
- Markets
- 1
Current odds
Snapshot from
As of Nov 22, 2026, 3:00 PM UTC, the highest-priced outcome on Kalshi is Any psychedelic substance for medical use at 17.5%.
Kalshi
- Any psychedelic substance for medical use17.5%
Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.
AI Analysis
Trader mode: Market mechanics, assumptions and risks
K 452.7K contracts
Reported volume · provider units
1
Saved contracts
0
Same-question pairs
Source snapshot: Nov 22, 2026, 3:00 PM UTC
This analysis was written from an earlier market snapshot, so its prices may be older than the odds above.
Snapshot observed Nov 11, 2026, 3:00 AM UTC. This analysis describes that snapshot and is not a live news update.
What the contract measures
The contract asks whether the FDA will approve any psychedelic substance for medical use before January 1, 2027 [1]. The source requires an FDA approval letter for an NDA or BLA authorizing marketing for human medical use in the United States, with a qualifying psychedelic as an active ingredient [1]. Complete Response Letters, tentative approvals, Emergency Use Authorizations, and expanded access or compassionate use authorizations do not satisfy the criterion [1]. The listed substances are described as illustrative rather than exhaustive [1]. Combination products and new indications for previously approved substances are excluded under the stated rules [1].
Reading the snapshot
The saved snapshot contains one market from one provider event. The provider observed it at 03:00:05 UTC on 11 November 2026, and the source was retrieved at 03:53:13 UTC on the same day [1]. The recorded Yes price is 0.195 and the No price is 0.805 [1]. These are snapshot prices, not executable quotes or verified probabilities. The source does not supply volume, so this snapshot says nothing about liquidity or the number of traders [1].
The listed end date for the market is Jan 8, 2027, 3:00 PM UTC, which differs from the contract wording "before Jan 1, 2027" [1]. The source states that the listed end time for the event is not supplied [1]. Readers should therefore rely on the contract rules for the qualifying window and treat the platform's end date as a separate field. The rules also state that the market will close and expire early if a qualifying event occurs under the stated conditions [1]. That is a rule about timing, not a notice of any announced event.
Because only one market was saved, there are no other outcomes or platforms to compare with this price.
What remains uncertain
The evidence does not explain why the prices are where they are. It contains no recent news, regulatory filings, or information about pending FDA decisions, so it cannot show whether a qualifying application exists. The sample is complete for this saved event, but the source notes that this does not establish that the provider lists every possible real-world outcome [1]. Prices may have changed after retrieval, so any later reading requires a new snapshot.
References
- Kalshi: Will the FDA approve any psychedelic substance for medical use this year?. Provider data observed Nov 11, 2026, 3:00 AM UTC.
AI-generated analysis based on market data. Not financial advice.
Saved Nov 11, 2026 UTCThis article was written from an earlier market snapshot and may be out of date. Use the dated market data and provider rules above for current information.
Overview
This PredictPedia entry covers a Kalshi contract asking whether the U.S. Food and Drug Administration (FDA) will approve any psychedelic substance for medical use before January 1, 2027 [1]. The contract resolves to Yes if the FDA approves a psychedelic substance for medical marketing within that window. The rules list examples of substances, including LSD, psilocybin, DMT, mescaline, MDMA, ibogaine, and ayahuasca, but state that this list is illustrative rather than exhaustive [1]. Other substances commonly recognized in scientific or FDA documentation as psychedelics, hallucinogens, or entactogens may also qualify [1]. The rules set a narrow standard for what counts as approval. It must be an FDA approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) that authorizes marketing of a drug or biologic for human medical use in the United States, with a qualifying psychedelic as an active ingredient [1]. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and export-only approvals do not satisfy the condition [1]. The rules also exclude some approvals that involve familiar ingredients. A combination product qualifies only if at least one active ingredient is a qualifying psychedelic that has not previously been FDA-approved through an NDA or BLA for any human medical indication [1]. A new indication, dosage, or formulation for a substance already approved before the contract's issuance does not qualify [1]. The rules give an example of a combination product approved for a new indication, where both active ingredients were already approved, and state that this would not satisfy the condition [1]. The rules also say that the market will close and expire early if a qualifying event occurs [1].
Historical Context
The Controlled Substances Act is the federal statute that establishes U.S. drug policy, regulating the manufacture, importation, possession, use, and distribution of certain substances [2]. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon [2]. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs [2]. According to a Wikipedia summary, psychedelic drugs were controlled substances in most countries as of 2021, and psychedelic therapy was not legally available outside clinical trials, with some exceptions [3]. That description is historical background as of 2021 and does not describe the regulatory status on the date of this entry.
Why It Matters
The contract measures a single regulatory event: whether the FDA grants a marketing approval for a psychedelic-containing medical product within a defined period [1]. Because the rules separate full marketing approvals from other authorizations and from new uses of existing ingredients, the outcome depends on the precise approval type and ingredient history rather than on general public attention to psychedelic research [1]. The background on federal drug control and on psychedelic therapy outside clinical trials helps explain why the question concerns a formal approval pathway [2][3].
Snapshot context
The latest published provider snapshot for this topic was observed on 2026-11-11 at 03:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]
Frequently Asked Questions
Does an approval of a new use for an already approved drug count?
No. Under the rules, an FDA approval of a new medical indication, dosage, or formulation for a substance whose active ingredient was already FDA-approved before issuance does not satisfy the condition [1].
Would an Emergency Use Authorization resolve the market to Yes?
No. The rules state that Emergency Use Authorizations, expanded access or compassionate use authorizations, Complete Response Letters, tentative approvals, and export-only approvals do not satisfy the condition [1].
Is the list of substances complete?
No. The rules describe the listed substances as illustrative and say other substances commonly recognized as psychedelics, hallucinogens, or entactogens may also qualify [1].
What date does the contract use?
The rules refer to approvals before January 1, 2027 [1]. The saved market record lists an end date of January 8, 2027 [1]. That listed date is a provider record and is not an announced FDA event or a confirmed closing time.
AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.
Related prediction markets
Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

Will the FDA approve any psychedelic substance for medical use before 2028?
K 500.41 contracts
Will the FDA approve retatrutide?
PM $599.3K · K 121.2K contractsFDA approves Retatrutide this year?
Kalshi: When will the FDA approve retatrutide (LY3437943)? (Before Jan 1, 2027)
Same question, fine print differs
Related or unreviewed contracts may settle differently. Their gap is not an equivalent-contract comparison.
Saved prices; check contract rules.

Will the FDA approve MDMA for PTSD?
K 13.7K contracts
Will the FDA approve VERVE-102?
K 1.8K contracts
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
K 28.1K contracts
Will the FDA approve intismeran autogene (V940/mRNA-4157)?
K 3.2K contractsMarket Insights
Price gaps of 2 pp+
0
Same-question pairs
0
No outcomes on this page have been reviewed as the same question on both platforms yet.
Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.
